In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Agios Pharmaceuticals, Inc.

https://www.agios.com/

Latest From Agios Pharmaceuticals, Inc.

Asia Deal Watch: Argo Partners RNAi Programs With Novartis In Major Biobucks Pact

Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.

Deal Watch Business Strategies

Agios Reports Phase III Success With Oral Drug For Thalassemia

The company hopes to position mitapivat as an oral treatment for patients across the thalassemia spectrum. A Phase III trial in non-transfusion-dependent alpha- or beta-thalassemia was positive.

Clinical Trials Blood & Coagulation Disorders

Hematologists Consider Where New Therapies Fit In Sickle Cell Treatment Paradigm

The first gene editing medicine and gene therapy for sickle cell disease were approved as the ASH meeting got under way, but novel oral drugs may be key to making treatment more accessible.

Gene Therapy Market Access

Sickle Cell Drug Development Gains Momentum Across Disease Spectrum

The recent ASH meeting began with US FDA approvals of the first genetic medicines for sickle cell disease, but doctors and biopharma companies still see a need for new oral therapies and other options. 

Clinical Trials Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register